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Introduction
Primary malignant melanoma (MM) accounts for 1% of all 
cancers. MM can occur in any region of the mucosal sites (i.e., 
mucosal melanomas): the oral cavity, esophagus, anus, con-
junctiva, or the gynecological tract. Primary vaginal melanoma 
accounts for less than 7% of all MMs, with less than 300 case 
reports worldwide, and 15 cases reported in the Republic 
of Korea [1]. Primary cervical melanoma is one of the rarest 
of these kinds of cancers; furthermore, it accounts for less 
than 2% of all MMs, with less than 50 cases reported in the 
literature [2]. Perhaps because of the rarity of primary cervi-
cal melanoma, there are no prospective, randomized, clinical 
trials assessing the effectiveness of various treatment options 
that have been undertaken in patients with melanomas of the 
female genital tract [3]. Thus, data are limited with respect to 
the basis for recommendation for the most efficacious treat-
ment. The overall prognosis of MM of the female genital tract 
is very poor because it is usually diagnosed at an advanced 
stage and it spreads hematogenously at early stages [1].
Patients with MM of the female genital tract present with 
symptoms, such as vaginal bleeding, vaginal discharge, and 
vaginal mass [1]. Diagnosis is made by histological and immu-
nological examination. Imaging studies are useful in identify-
ing the primary site of malignancy and in determining exten-
sion of the mass. There are a few different staging systems 
that coexist for cervical MM and vaginal MM, respectively. 
The recommended therapy for primary MM of the female 
genital tract is surgical excision. In cervical MM, radical surgery 
is preferred. Generally, radical hysterectomy with pelvic lymph 
node dissection and partial vaginectomy followed by radiation 
therapy (RT) delivered externally, such as external beam RT, or 
RT delivered internally, e.g., intracavitary RT, is most common-
ly used in treating gynecological cancers. On the other hand, 
in vaginal MM, wide local excision is the treatment of choice. 
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It is highly debatable whether or not lymphadenectomy is es-
sential. There are limited reports about the usefulness of adju-
vant immunotherapy, RT, or chemotherapy. 
Case report
1. Case 1 
A 70-year-old female visited the emergency room with a left 
thigh pain. After physical evaluation, the patient underwent a 
left thigh magnetic resonance imaging (MRI) which showed a 
large cervical cancer with involvement of the vagina, bladder, 
and parametrium, in addition to multiple bony metastases of 
the proximal femur, acetabulum, and both iliac bones (Fig. 1). 
A gynecological examination showed an exophytic, hard, 
and pigmented mass, involving the cervix. A colposcopy-guid-
ed cervical biopsy was performed and that tissue was sent 
to the pathology laboratory for examination. These sheets of 
malignant cells revealed atypical features such as granular cy-
toplasm and prominent eosinophilic nucleoli (Fig. 2A, micro-
scopic sections from the biopsy). These atypical cells showed 
a diverse morphology, from the spindle to epithelioid cells, 
Fig. 1. Magnetic resonance imaging findings. (A) About 8.6×7.3-cm enhancing cervical mass shows an invasion to the vaginal, bladder, 
and parametrium. It demonstrates mixed intermediate to subtle high signal intensity on T1WI. The white arrow indicates left sacral metas-
tasis. (B) Right obturator lymph node metastasis is noted (yellow arrow). It shows heterogeneous intermediate to subtle high signal inten-
sity on T2WI. (C) Right obturator lymph node metastasis and diffuse pelvic bone metastasis are noted (red arrow). It shows heterogeneous 
enhancement after contrast administration. 
A                                             B                                              C
Fig. 2.  (A) Highly atypical sheets of malignant cells reveal sufficient granular cytoplasm and prominent eosinophilic nucleoli. The atypical 
cells show diverse morphology from the spindle to epithelioid cells, and mixed in brownish pigments and abundant blood vessels (H&E, 
×400 ). (B) Immunohistochemical stains for HMB45 (×200) were done. Antibodies against HMB 45 (melanosome) disclose diffused posi-
tive reaction against tumor cells. (C) Immunohistochemical stains for S100 (×100) were done. Antibodies against S100 protein disclose 
diffused positive reaction against tumor cells.
A                                             B                                              C
www.ogscience.org 417
Jae Hoon Lee, et al.  Malignant melanoma of cervix and vagina 
and mixed in brownish pigments and abundant blood ves-
sels. Next, these cells were subjected to immunohistochemical 
analysis, that is, they were stained with HMB-45 and S100. 
The antibodies against HMB-45 (melanosome) and S100 pro-
tein disclosed a diffused positive (Fig. 2B, C) reaction against 
tumor cells. Bearing in mind all the aforementioned findings, 
we diagnosed cervical MM. 
The patient received focal argon laser treatment four times 
and went to a long-term acute care hospital to spend the rest 
of her life. She died two months after the initial diagnosis. 
2. Case 2
A 35-year-old woman, para 2, who presented with a history 
of intermittent vaginal bleeding for five months, was referred 
to a tertiary healthcare institution. The patient was diagnosed 
with a vaginal MM by her private physician after a punch 
biopsy of a pinkish ulcerative lesion at the lower vagina. Af-
ter a colposcopic examination, the following was noted: a 
20-mm-sized erosive lesion at the 9 o’clock position of the 
lower vagina (Fig. 3A). After a positron emission tomography- 
computed tomography (CT), a mild fluorine-18-deoxyglucose 
Fig. 3.  (A) Colposcopic findings of primary malignant melanoma at vagina. It shows pinkish ulcerative lesion at lower vagina. (B) posi-
tron emission tomography-computed tomography (PET-CT) findings of recurrence of vaginal melanoma at left inguinal lymph node (white 
arrow). (C) PET-CT findings of recurrence of vaginal melanoma at right inguinal node (yellow arrow). (D) PET-CT findings of metastasis to 
multiple organs 37 months after the initial diagnosis, following three times of surgery and adjuvant therapy. 
A                                             B
C  D
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uptake was shown at several lymph nodes in the left pelvic 
cavity. 
The patient further underwent a radical vaginectomy, a total 
abdominal hysterectomy, a bilateral salpingo-oophorectomy, 
and a left pelvic lymphadenectomy. A histologic examination 
revealed a 2.0×2.0-cm-sized nodular lesion with a depth of 
invasion of 700 μm; and a 0.4×0.2-cm-sized satellite lesion 
with a depth of invasion of 0.18 cm. 
Immunohistochemically, the main lesion was stained with 
HMB-45 and S100; both of these immunostains were found 
to be positive. The lymph nodes, as well as surgical margins, 
were free from tumor. The patient underwent adjuvant im-
munotherapy with a high dose of interferon alpha2 beta. The 
patient was followed regularly in clinic and was disease-free 
for seven months. 
Five months after completing adjuvant immunotherapy, a 
positron emission tomography-CT revealed an enlarged lymph 
node at the left inguinal area; an ensuing biopsy definitively 
determined that this condition was metastatic melanoma (Fig. 
3B). The patient then underwent a left inguinal lymphadenec-
tomy. Subsequently, the patient received adjuvant fraction-
ated RT to the left inguinal area, with a weekly dose 48 Gy, 
for four times. After completion of the adjuvant fractionated 
RT, there was adjuvant chemotherapy with dacarbazine 1.8-
mg body surface area applied at 3-week intervals, two times. 
However, a later CT, which was taken for evaluation of the 
treatment response, revealed an enlarged lymph node at the 
right inguinal area, opposite to the one that was previously 
biopsied (left); and it was then proven to be a metastatic 
melanoma (Fig. 3C). The patient underwent a third operation, 
which was 14 months after the diagnosis and six months 
after her second operation. The patient underwent adjuvant 
fractionated RT to the right inguinal area, with a weekly dose 
48 Gy, for four times. 
Four months after the patient’s third surgery, multiple lung 
metastases were found by an imaging and examination. The 
patient underwent palliative chemotherapy, eight times, with 
docetaxel 35 mg/m2 and a carboplatin area under curve 3 
regimen; and chemotherapy, four times, with a cisplatin 30 
mg and a vinblastine 1.8 mg regimen. Despite that chemo-
therapy, the disease progressed to the liver, left kidney, and 
duodenum (Fig. 3D). The patient expired by multiple organ 
failure, which was 37 months after the initial diagnosis. 
Four months after her third surgery, multiple lung metastasis 
were found by imaging study. She underwent 8 times of pal-
liative chemotherapy with docetaxel 35 mg/m2 + carboplatin 
area under curve 3 regimen and 4 times of chemotherapy 
with cisplatin 30 mg + vinblastine 1.8 mg regimen. Despite 
chemotherapy, disease progressed to liver, left kidney and 
duodenum. At last, she expired by multi organ failure, which 
was 37 months after the initial diagnosis. 
Discussion 
Primary MM of the female genital tract is very rare; further-
more, and most of the melanomas reported were of the vul-
va. In particular, primary cervical melanoma is one of the rar-
est tumors, with less than 50 cases reported in the literature 
[2]. Melanomas of the female genital tract are diagnosed at 
an advanced stage and they spread hematogenously at early 
stages through the vascular plexus around the female genital 
tract; thus, the overall prognosis is very poor [1]. The most 
recent National Cancer Database report indicated a 5-year 
survival of 11.4% for female genital tract melanoma [4].    
Vaginal bleeding (63.6%), vaginal mass (15.9%), and vagi-
nal discharge (15.9%) are common symptoms of female geni-
tal tract MM [1,5]. The gross appearance of female genital 
tract MM is pinkish in many cases, and it is commonly accom-
panied by ulceration compared to cutaneous MM that de-
velops from a nevus [3]. In the first case, the primary cervical 
MM showed a cervical mass in the exophytic area, which was 
hard and pigmented, However in the second case, a pinkish 
ulcerative lesion was observed in the lower vagina. The gross 
findings of vaginal MM include various shapes of lesions, such 
as solitary, multifocal, superficial spreading, and a nodular 
shape [6].
Diagnosis of MM is made by histological and immunologi-
cal examination using special immunostains such as those for 
S100 and HMB-45 [7]. To identify the primary site of cervical 
or vaginal MM, a thorough physical examination and imag-
ing study are essential. Although there are few reports of 
metastasis from malignancies of kidney and breast, metastasis 
to the lower female genital tract is rare and mainly from ad-
jacent organs; bladder and colorectum [8,9]. CT or MRI may 
be helpful to determine the extension, as well as the degree 
of cancer involvement. MRI can distinguish melanoma from 
other tumors because of a distinct signal pattern for melanin, 
i.e., high signal intensity on T1-weighted magnetic resonance 
images and low signal intensity on T2-weighted magnetic 
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resonance images [10]. In both the cases, imaging studies 
were performed for detecting the primary site of malignancy 
instead of cystoscopy or colonoscopy.
There are two staging systems for primary MM of the cervix. 
Morrow and DiSaia have suggested the primary cutaneous 
melanoma staging system based on the thickness of the pri-
mary lesion, which is more clinically applicable to cervical MM 
compared to the International Federation of Gynecology and 
Obstetrics (FIGO) staging system for cervical cancer. However, 
the FIGO staging system for cervical cancer has been found to 
correlate well with the prognosis [11].  
There are two coexisting staging systems for primary MM of 
the vagina as well. Recently, a few studies reported that the 
AJCC (American Joint Committee on Cancer) staging sytem 
based on the guidelines for cutaneous MM better reflects the 
overall prognosis for vaginal melanoma and is more adaptable 
than the FIGO staging for vaginal MM [1,3]. In these studies, 
invasion depth, margin, ulceration, and lymph node status 
were the major prognostic factors.
The overall prognosis for this kind of cancer is very poor. 
In a review of the literature for primary cervical melanoma, 
the 5-year survival rate for stage IA was 25% in the thirteen 
reported cases. The 5-year survival rate for stage II was 14%, 
and the 5-year survival rate for stages III and IV was 0% [10].  
The recommended therapy for primary MM of the female 
genital tract is surgical excision. The therapy of choice for 
primary cervical MM is radical surgery, followed by focal ra-
diotherapy; i.e., radical hysterectomy with pelvic lymph node 
dissection and partial vaginectomy, followed by RT such as 
external beam RT or intracavitary RT. However, from the clini-
cal experience presented in the literature, MMs are generally 
considered to be radioresistant. Thus, irradiation is only useful 
in palliative therapy of a patient who is deemed unsuitable 
for radical surgery [12]. A patient can receive a single-agent 
or combination chemotherapy, using melphalan, vincristine, 
procarbazine, and bis-chloroethylnitrosourea, or a combina-
tion of bis-chloroethylnitrosourea, vincristine, and dimethyl 
triazeno imidazole carboxamide. However, the regression of 
tumors is transient [12]. Immunotherapy has also been intro-
duced: the BCG (Bacille Calmette-Guérin) with interferon or 
interleukin-2. The results are not so promising [13].
As seen in the second case, surgery is the treatment of 
choice for vaginal MM. In a study of patients with vaginal 
MM at the University of Texas MD Anderson Cancer Center, 
the median survival was significantly different for women with 
vaginal MM who underwent surgery, compared to those who 
received other therapeutic modalities without surgery (24.3 
to 34.4 vs. 8.7 months, respectively) [12]. However, there has 
been a debate with respect to the extent of surgery, i.e., re-
cent reports have stated that wide local excision can achieve 
survival rates equivalent to radical surgery [1,12,14]. For a 
routine lymphadenectomy, there is insufficient evidence for a 
low rate of regional lymph node metastasis [1,12]. Although 
sentinel lymph node biopsy is gaining in popularity due to 
low morbidity, further study is needed [15]. In spite of various 
kinds of recommendations, each patient’s treatment should 
be individualized based on the disease status. For example, 
if local excision is impossible and there is suspicion of lymph 
node metastasis, radical surgery with lymphadenectomy may 
be a reasonable option.
There is limited evidence about the optimal adjuvant ther-
apy for vaginal MM. Although MM is known to be resistant 
to radiotherapy and chemotherapy, recent studies with a 
small sample size showed that adjuvant treatment (including 
radiotherapy and chemotherapy) prolonged progression-free 
survival in vaginal MM patients who underwent wide local 
excision [1]. Immunotherapy with interferon is a widely used 
adjuvant therapy. Two agents (ipilimumab and vemurafenib) 
were approved by the US Food and Drug Administration in 
2011 for the treatment of unresectable or metastatic cutane-
ous melanoma and they show promise with respect to the 
treatment of vaginal MM.
In conclusion, when patients visit the clinic with a mass 
or vaginal bleeding, primary MM should be considered as 
a differential diagnosis of other neoplasms. The pathologic 
diagnosis is usually confirmed using special stains and im-
munohistochemistry, if required. The treatment of choice for 
female genital tract MM is surgical excision and the prognosis 
is generally poor.  
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